Wedbush Predicts Lower Earnings for Dianthus Therapeutics

Key Points

• Wedbush has lowered earnings estimates for Dianthus Therapeutics, predicting a Q3 2025 EPS of ($0.83), down from ($0.81), while maintaining an "Outperform" rating with a price target of $42.00.
• The company reported a Q2 loss of ($0.88) EPS, missing analyst expectations, and had a significantly negative net margin of 2,364.56% with revenues falling short of projections.
• Despite the negative earnings outlook, Dianthus Therapeutics' stock has a consensus rating of "Buy" from analysts, with a notable average target price of $54.00.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Stock analysts at Wedbush dropped their Q3 2025 earnings per share (EPS) estimates for Dianthus Therapeutics in a research report issued on Thursday, August 21st. Wedbush analyst L. Chico now expects that the company will post earnings of ($0.83) per share for the quarter, down from their previous estimate of ($0.81). Wedbush currently has a "Outperform" rating and a $42.00 target price on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. Wedbush also issued estimates for Dianthus Therapeutics' Q4 2025 earnings at ($0.87) EPS and FY2025 earnings at ($3.40) EPS.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The business had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million.

Other research analysts have also issued research reports about the company. William Blair began coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They set an "outperform" rating for the company. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Finally, Robert W. Baird cut their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $54.00.

Dianthus Therapeutics Trading Down 5.0%

Shares of NASDAQ DNTH traded down $1.24 during midday trading on Monday, hitting $23.57. 345,906 shares of the company's stock were exchanged, compared to its average volume of 382,629. Dianthus Therapeutics has a 12-month low of $13.36 and a 12-month high of $32.27. The company has a market cap of $758.72 million, a price-to-earnings ratio of -7.25 and a beta of 1.43. The business's fifty day moving average price is $20.60 and its two-hundred day moving average price is $20.06.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DNTH. JPMorgan Chase & Co. grew its holdings in shares of Dianthus Therapeutics by 14.0% in the fourth quarter. JPMorgan Chase & Co. now owns 12,129 shares of the company's stock worth $264,000 after purchasing an additional 1,490 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Dianthus Therapeutics by 7.4% during the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock valued at $251,000 after acquiring an additional 790 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Dianthus Therapeutics by 23.7% during the fourth quarter. Legal & General Group Plc now owns 12,319 shares of the company's stock valued at $269,000 after acquiring an additional 2,363 shares in the last quarter. Barclays PLC raised its holdings in shares of Dianthus Therapeutics by 2.6% during the fourth quarter. Barclays PLC now owns 42,766 shares of the company's stock valued at $933,000 after acquiring an additional 1,082 shares in the last quarter. Finally, MetLife Investment Management LLC raised its holdings in shares of Dianthus Therapeutics by 3.1% during the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company's stock valued at $313,000 after acquiring an additional 433 shares in the last quarter. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.